IL144216A0 - Use of angiotensin ii receptor antagonists for treating acute myocardial infarction - Google Patents

Use of angiotensin ii receptor antagonists for treating acute myocardial infarction

Info

Publication number
IL144216A0
IL144216A0 IL14421600A IL14421600A IL144216A0 IL 144216 A0 IL144216 A0 IL 144216A0 IL 14421600 A IL14421600 A IL 14421600A IL 14421600 A IL14421600 A IL 14421600A IL 144216 A0 IL144216 A0 IL 144216A0
Authority
IL
Israel
Prior art keywords
angiotensin
myocardial infarction
receptor antagonists
acute myocardial
treating acute
Prior art date
Application number
IL14421600A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL144216(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL144216A0 publication Critical patent/IL144216A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL14421600A 1999-01-26 2000-01-24 Use of angiotensin ii receptor antagonists for treating acute myocardial infarction IL144216A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99810061 1999-01-26
US46866499A 1999-12-21 1999-12-21
PCT/EP2000/000525 WO2000044378A1 (en) 1999-01-26 2000-01-24 Use of angiotensin ii receptor antagonists for treating acute myocardial infarction

Publications (1)

Publication Number Publication Date
IL144216A0 true IL144216A0 (en) 2002-05-23

Family

ID=26153740

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14421600A IL144216A0 (en) 1999-01-26 2000-01-24 Use of angiotensin ii receptor antagonists for treating acute myocardial infarction
IL144216A IL144216A (en) 1999-01-26 2001-07-09 Use of angiotensin II receptor antagonists in the preparation of drugs for the treatment of acute myocardial infarction

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL144216A IL144216A (en) 1999-01-26 2001-07-09 Use of angiotensin II receptor antagonists in the preparation of drugs for the treatment of acute myocardial infarction

Country Status (25)

Country Link
EP (2) EP1146872B1 (xx)
JP (1) JP2002535367A (xx)
KR (1) KR100674053B1 (xx)
CN (1) CN1337879A (xx)
AT (1) ATE330599T1 (xx)
AU (1) AU766453C (xx)
BR (1) BR0007686A (xx)
CA (1) CA2360691A1 (xx)
CY (1) CY1105257T1 (xx)
CZ (1) CZ20012682A3 (xx)
DE (1) DE60028928T2 (xx)
DK (1) DK1146872T3 (xx)
ES (1) ES2265910T3 (xx)
HK (1) HK1041808B (xx)
HU (1) HUP0105199A3 (xx)
ID (1) ID29818A (xx)
IL (2) IL144216A0 (xx)
NO (1) NO20013459L (xx)
NZ (1) NZ513039A (xx)
PL (1) PL197161B1 (xx)
PT (1) PT1146872E (xx)
RU (2) RU2298405C2 (xx)
SI (1) SI1146872T1 (xx)
SK (1) SK10522001A3 (xx)
WO (1) WO2000044378A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038676A1 (en) * 1998-12-23 2000-07-06 Novartis Ag Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
EP1314425A4 (en) * 2000-08-30 2004-06-02 Sankyo Co MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
US7076287B2 (en) 2000-12-29 2006-07-11 Ge Medical Systems Information Technologies, Inc. System and method for detecting new left bundle branch block for accelerating treatment of acute myocardial infarction
EP1448190A2 (en) * 2001-10-18 2004-08-25 Novartis AG Salts formed of an at1-receptor antagonist and a cardiovascular agent
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
PL373202A1 (en) * 2002-05-17 2005-08-22 Novartis Ag Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
SE0302331D0 (sv) * 2003-08-29 2003-08-29 Astrazeneca Ab New use II
WO2005030202A1 (en) * 2003-09-26 2005-04-07 Novartis Ag Use of angiotensin ii receptor antagonists for treating cerebrovascular disorders
WO2005053687A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Combination of organic compounds
WO2009087116A1 (en) * 2008-01-11 2009-07-16 Novartis Ag Use of spp100 for the treatment of acute mi
CN104086623B (zh) * 2014-07-02 2017-05-24 牡丹江友搏药业有限责任公司 一种新的具有降压和细胞保护作用的化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027208D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
EP0577025A3 (de) * 1992-07-01 1998-02-04 Hoechst Aktiengesellschaft Angiotensin-II-Rezeptorantagonisten zur Behandlung und Prophylaxe von koronaren Herzerkrankungen
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
DE4432860A1 (de) * 1994-09-15 1996-03-21 Merck Patent Gmbh Imidazopyridine
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US5795904A (en) * 1996-12-06 1998-08-18 Merck & Co., Inc. Enhanced functional recovery of the heart by losartan treatment after an ischemic attach

Also Published As

Publication number Publication date
AU2439700A (en) 2000-08-18
CN1337879A (zh) 2002-02-27
IL144216A (en) 2007-07-04
PT1146872E (pt) 2006-10-31
HK1041808B (zh) 2007-01-19
HK1041808A1 (en) 2002-07-26
NZ513039A (en) 2003-11-28
AU766453C (en) 2004-11-25
KR100674053B1 (ko) 2007-01-25
ID29818A (id) 2001-10-11
DE60028928D1 (de) 2006-08-03
ATE330599T1 (de) 2006-07-15
ES2265910T3 (es) 2007-03-01
CZ20012682A3 (cs) 2001-10-17
DK1146872T3 (da) 2006-10-16
NO20013459L (no) 2001-09-05
PL197161B1 (pl) 2008-03-31
KR20020002379A (ko) 2002-01-09
JP2002535367A (ja) 2002-10-22
CA2360691A1 (en) 2000-08-03
RU2006135205A (ru) 2008-04-10
RU2345790C2 (ru) 2009-02-10
EP1146872A1 (en) 2001-10-24
AU766453B2 (en) 2003-10-16
DE60028928T2 (de) 2007-01-04
NO20013459D0 (no) 2001-07-12
BR0007686A (pt) 2001-11-06
SI1146872T1 (sl) 2006-12-31
EP1714651A1 (en) 2006-10-25
HUP0105199A2 (hu) 2002-04-29
RU2298405C2 (ru) 2007-05-10
HUP0105199A3 (en) 2004-11-29
WO2000044378A1 (en) 2000-08-03
CY1105257T1 (el) 2010-03-03
SK10522001A3 (sk) 2001-12-03
EP1146872B1 (en) 2006-06-21

Similar Documents

Publication Publication Date Title
CY1105257T1 (el) Χρηση των ανταγωνιστων των υποδοχεων της αγγειοτενσινης ii στην θepαπεια του οξεος εμφραγματος του μυοκαρδιου
IL127244A0 (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
HK1080456A1 (en) N-substituted hydromorphones and the use thereof
MX9603259A (es) Tratamiento de glaucoma normotensivo con antagonistas de angiotensina ii.
WO2002099388A3 (en) Benzodiazepine bradykinin antagonists
ZA200108130B (en) Treatment of pulmonary hypertension.
IL147977A0 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
HUP0202734A3 (en) Use of pegylated interfron alfa-ccr5 antagonist combination for hiv therapy
ATE295183T1 (de) Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
AP9801202A0 (en) Atropisomers of 3-heteroaryl-4(3H)-quinazolinones.
AP2002002501A0 (en) Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
BG105651A (en) Vitronectin receptor antagonist
RS78004A (xx) Farmaceutska kompozicija inhibitora pde4 ili inhibitora pde3/4 i antagoniste histaminskih receptora
CA2055948A1 (en) Use of a combination of angiotensin-converting enzyme inhibitor and calcium antagonist for the treatment of proteinuria
IL120495A0 (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
CA2416879A1 (en) Methods of treating cancer and the pain associated therewith using endothelin antagonists
WO2001017959A3 (en) Vitronectin receptor antagonists
WO2000007544A3 (en) Vitronectin receptor antagonists
WO2000076457A3 (en) Il-8 receptor antagonists
ZA200405437B (en) Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for the prevention or treatment of pathogenic conditions.
EP1095655A3 (en) NK-1 receptor antagonists and eletriptan for the treatment of migraine
IL123536A0 (en) 5-HT3 Receptor antagonists for dyskinesia
MX9802372A (es) N-heterociclos condensados, sustituidos con benciloxi, procedimiento para su preparacion y su empleo como antagonistas de receptores de bradiquinina.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed